Tech Company Financing Transactions
CinDome Pharma Funding Round
CinDome Pharma, based in Cincinnati, secured $40 million from Perceptive Advisors.
Transaction Overview
Company Name
Announced On
5/16/2024
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the ongoing enrollment and evaluation of deudomperidone in the Phase 2 envision3D study in adults with diabetic gastroparesis and position itself for registrational trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5375 Medpace Way
Cincinnati, OH 45227
USA
Cincinnati, OH 45227
USA
Phone
Undisclosed
Website
Email Address
Overview
CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis. Gastroparesis, or delayed gastric emptying, occurs when the stomach does not empty normally, causing abdominal discomfort, severe nausea, or vomiting after eating. These symptoms can be hard to manage and lead to other complications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jon Isaacsohn
Browse more venture capital transactions:
Prev: 5/16/2024: HEPHAISTOS-Pharma venture capital transaction
Next: 5/16/2024: Phenomix Sciences venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs